engene.com (ENGN) - Market Value to Book Value Ratio
enGene Holdings Inc. (ENGN) relies on external contractors for plasmid synthesis, maintaining quality control through international audits. The business faces intense pressure from traditional biotech behemoths in the non-viral treatment sector. This price action on GURU.Markets, where the indicator stands at 0.45, complements data on the development of multipurpose gene therapies to combat immune pathologies and cancer, which minimizes project risks.
enGene Holdings Inc (ENGN) - metric breakdowns and financial figures
- market value and analyst target forecast:
- market capitalization indicators:
- book capitalization data:
- debt obligations and liquidity statistics:
- earnings and valuation multiples indicators:
Basic company analysis:enGene Holdings Inc. - ENGN
This indicator determines the stability of the company's market premium by comparing the current share price with the volume of net assets to assess investor confidence in future growth. By analyzing the extent to which market capitalization exceeds book value, one can understand the market's willingness to pay a premium for enGene Holdings Inc. (ENGN) innovations in non-sterile gene therapy and the commercial potential of their scientific developments.
Competitor analysis
argenx SE (ARGX) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio BNTX|Market Value to Book Value Ratio abivax.com|ADMA Biologics Inc - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio PTGX|IMVT (Immunovant Therapeutics) - Market Value to Book Value|Market Capitalization to Book Value Ratio KNSA (Kiniksa Pharmaceuticals)|Market Capitalization to Book Value Ratio grifols.com GRFS|ADPT - Market Value to Book Value Ratio|Market Value to Book Value CLDX (Celldex Therapeutics Inc)|Aurinia Pharma (AUPH) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio BioCryst Corp|VERA (Vera Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio dianthustx.com|Market Cap to Net Assets Ratio PHVS (Pharvaris)|ABCL (AbCellera Biologics) - Market Value to Book Value|Market Capitalization to Book Value Ratio TRML (Tourmaline Corp)|Market Capitalization to Book Value Precigen Corp (PGEN)|PHAR - Market Value to Book Value Ratio|nektar.com (NKTR) - Market Cap to Net Assets Ratio|Upstream Bio (UPB) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Zenas Bio|Market Cap to Net Assets Ratio IMNM|Market Capitalization to Book Value Ratio Gossamer Bio Corp.|Market Value to Book Value Ratio KalVista Pharmaceuticals (KALV)|septerna.com - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio PVLA (Pieris Pharmaceuticals, Inc.)|Savara Inc (SVRA) - Market-to-Book Ratio|Rigel Pharmaceuticals Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio AnaptysBio Inc.|Astria Therapeutics (ATXS) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio RAPT|JBIO (Aerovate Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|ACRS - Market Value to Equity Ratio|Market Capitalization to Book Value Ratio KYTX|TLSA - Market-to-Book Ratio|Market Value to Book Value Ratio Cabaletta Bio, Inc. CABA|VTYX: Capitalization to Book Value Ratio|Theratechnologies - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Avalo Therapeutics, Inc.|ELDN (Eledon) - Market Cap to Net Assets Ratio|Agenus, Inc - Market Value to Book Value|CLYM (Climb Bio Inc) - Market Capitalization to Book Value Ratio|ZURA: Market Value to Book Value|Market Value to Book Value Ratio aTyr Pharma (ATYR)|ADAG - Market-to-Book Ratio|Market Value to Book Value Ratio Ikena Oncology IMA|Shattuck Labs Inc - Market Value to Book Value Ratio|Equillium Bio - Market Capitalization to Book Value Ratio|CNTB (Connect Biopharma) - Capitalization to Book Value Ratio|IMUX: Market Capitalization to Book Value Ratio|ATRA - Market Capitalization to Book Value|Market Value to Book Value Ratio InflaRx NV|Capitalization to Book Value Ratio XFOR (X4 Pharmaceuticals, Inc)|Market Capitalization to Book Value Ratio ACET|celularity.com (CELU) - Market Value to Equity Ratio|Market Value to Book Value Ratio INmune Bio INMB|Market Capitalization to Book Value Barinthus Biotherapeutics PLC (BRNS)|KZR: Market Cap to Net Assets Ratio|Market Value to Book Value SABS (SAB Biotherapeutics Inc)|AKTX: Market Capitalization to Book Value Ratio|ENLV - Market Capitalization to Book Value|Market Value to Book Value Ratio Q32 Bio Inc|Capitalization to Book Value Ratio GOVX (GeoVax Labs)|Market Capitalization to Book Value Ratio EDSA|Market Cap to Net Assets Ratio iBio Corporation IBIO|Carisma Therapeutics Inc. - Market Cap to Net Assets Ratio|Market Capitalization to Book Value xtlbio.com (XTLB)|Bolt Bio - Market Capitalization to Book Value Ratio|Market-to-Book Ratio HCW Biologics Inc.|aptevotherapeutics.com (APVO) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio AIM|ADTX (Aditxt Inc.) - Market Capitalization to Book Value Ratio|GRI - Market Value to Equity Ratio|Market Value to Book Value Ratio XORTX Therapeutics (XRTX)|Vyome Holdings Inc. - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Revelation Bio REVB|INDP (Indaptus Corp) - Market Capitalization to Net Assets|Scinai Immunotherapeutics - Market Capitalization to Book Value Ratio|Market Value to Book Value CALI (CalciMedica, Inc.)|AFMD: Market Capitalization to Book Value Ratio|Allakos (ALLK) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio HOOKIPA Pharma, Inc.|IGMS: Market Value to Book Value|Market Value to Book Value Ratio iTeos Therapeutics (ITOS)|Market Cap to Net Assets Ratio oceanbiomedical.com OCEA|Market Capitalization to Book Value Ratio TCBP (TC BioPharm)|Market Capitalization to Book Value Ratio Third Harmonic Bio Inc. THRD